Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 ( <scp>JAK2</scp> ), in patients with myelofibrosis and low pretreatment platelet counts-Reference-Cited by-同舟云学术

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 ( JAK2 ), in patients with myelofibrosis and low pretreatment platelet counts

Published:2022-04-27 Issue:2 Volume:198 Page:317-327
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Harrison Claire N.¹^ORCID,Schaap Nicolaas²,Vannucchi Alessandro M.³^ORCID,Kiladjian Jean‐Jacques⁴,Passamonti Francesco⁵,Zweegman Sonja⁶,Talpaz Moshe⁷,Verstovsek Srdan⁸^ORCID,Rose Shelonitda⁹,Zhang Jun⁹,Sy Oumar⁹,Mesa Ruben A.¹⁰^ORCID

Affiliation:

1. Department of Clinical Haematology Guy's and St Thomas' NHS Foundation Trust London UK

2. Radboud University Medical Centre Nijmegen Nijmegen Netherlands

3. Center for Research and Innovation of Myeloproliferative Neoplasms AOU Careggi, University of Florence Florence Italy

4. Centre d'Investigations Cliniques, INSERM, CIC1427 AP‐HP, Hôpital Saint‐Louis, Université de Paris Paris France

5. Department of Medicine and Surgery University of Insubria Varese Italy

6. Department of Hematology Amsterdam UMC, Vrije Universiteit Amsterdam Amsterdam Netherlands

7. University of Michigan Comprehensive Cancer Center Ann Arbor Michigan USA

8. The University of Texas MD Anderson Cancer Center Houston Texas USA

9. Bristol Myers Squibb Princeton New Jersey USA

10. Mays Cancer Center at UT Health San Antonio MD Anderson San Antonio Texas USA

Funder

Bristol-Myers Squibb

Sanofi

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18207

Reference30 articles.

1. Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

2. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

3. JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

4. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms

5. JAK/STAT signaling in hematological malignancies

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

2. Ph-Negative Chronic Myeloproliferative Neoplasms;Comprehensive Hematology and Stem Cell Research;2024

3. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis;Cancers;2023-12-28

4. The management of myelofibrosis: A British Society for Haematology Guideline;British Journal of Haematology;2023-12

5. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis;Future Oncology;2023-11-22